At the Korean Pavilion of the world’s largest biotechnology and life sciences exhibition, a foreign participant requesting a partnering meeting enthusiastically expressed interest in the Korean biotech market with the phrase, “I Love KOREA, We Love KOREA!” Korean companies, each conducting over 100 to 200 meetings on site, are showcasing the rising global stature of K-Bio.

바카라사이트 USA 2025, the largest and most comprehensive event in the global 바카라사이트tech industry, opened on June 16 at the Boston Convention and Exhibition Center. The event gathers over 20,000 leaders from across the life sciences ecosystem. Korea has the third-largest national presence, following the U.S. and Canada, using this global stage to promote brand visibility, technological exchange, and global collaboration.

The four-day event runs from June 16 to 19 and covers 20 major topics, including AI, digital health, next-generation 바카라사이트logics, and business development. Over 100 speakers will lead more than 180 sessions, offering insights into cutting-edge 바카라사이트tech trends. An estimated 60,000 partnering meetings will take place among more than 10,000 participants.

From Korea, leading players like Celltrion, Samsung 바카라사이트logics, Lotte 바카라사이트logics, SK 바카라사이트pharmaceuticals, Kolon Life Science, and Samjin Pharmaceutical are present. Innovative 바카라사이트tech firms such as Alteogen, Kangstem 바카라사이트tech, EN Cell, HLB Cell, and GeneCraft are also engaging in presentations, booth exhibitions, and business meetings.

Celltrion, attending for the 16th consecutive year, is spotlighting its new drug open innovation strategies. A representative stated, “Through over 100 partnering meetings, we aim to showcase our vision and capabilities while seeking new global collaborations.”

Samsung Biologics, in its 13th year at BIO USA, expanded the number of meeting rooms to facilitate more partnering sessions. A company representative said, “This year, we’re also actively promoting our new organoid-based drug screening service.”

Lotte Biologics is highlighting its dual-site CDMO service, connecting its facilities in New York and Songdo. A representative explained, “With our 360,000-liter plant in Songdo set to be completed by late next year, we aim to broaden our global footprint.”

SK Biopharmaceuticals, participating with a dedicated booth for the first time, is pursuing global expansion of cenobamate, its successful epilepsy treatment in the U.S. “We're here to build brand recognition and explore new markets,” said a company official.

The Korea Pavilion, co-organized by KoreaBIO and KOTRA, supports 51 companies—representing the second-largest national delegation. On day one, it hosted an Open Stage where companies such as CdmoGen (mRNA vaccines), Biospero (organ-on-a-chip), Medi AI PLUS (clinical data curation), BionSight (AI drug discovery), and AprilBio (immuno-oncology and ADCs) showcased their platforms.

Alteogen, which recently announced a new global pharma partnership, is drawing strong interest. “Several major companies have shown interest in our pipeline. We plan to engage potential partners directly during BIO USA,” said a representative.

EN Cell is promoting its single-use bioprocessing consumables, aiming to expand into global markets. “While global pharma dominates 90% of this market, we see overseas growth as a chance to strengthen our position,” said a company spokesperson.

GeneCraft introduced its proprietary AAV platform technology, designed to enhance gene therapy productivity by over 40–50%. “Our structural optimization of ITR sequences delivers consistent results across various genes and AAV serotypes,” said a representative. The platform avoids productivity losses seen in traditional capsid engineering.

Its lead candidate, RX001 for KRAS-mutant NSCLC, recently received Phase 1 trial approval in Korea. “The construct includes our SuperTR technology and meets GMP and GLP standards,” the representative emphasized.

Kangstem Biotech is advancing three major programs, including the osteoarthritis treatment ‘OSCA,’ designed to regenerate joint tissue and offer immediate pain relief with a single injection. “This is the only non-surgical alternative for patients with limited treatment options,” a representative stated. The company is also developing a skin organoid platform, drawing interest from over 30 multinational partners.

“Our Phase 2a trial in Korea is underway, with domestic tech transfer completed. We are now pursuing global licensing,” he added. “While most products reduce VAS pain scores to around 40 after three months, our therapy brings it near zero.”

BIO President and CEO John F. Crowley commented, “This convention brings together scientists, innovators, and advocates to transform ideas into life-saving solutions. At a time of global health demands, biotechnology is ready to meet the challenge.”